Fulcrum Therapeutics (FULC) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' Income towards Parent Company rose 968.38% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.5 million, marking a year-over-year decrease of 19843.69%. This contributed to the annual value of -$9.7 million for FY2024, which is 9000.87% up from last year.
- As of Q3 2025, Fulcrum Therapeutics' Income towards Parent Company stood at -$19.6 million, which was up 968.38% from -$17.3 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Income towards Parent Company ranged from a high of $55.4 million in Q2 2024 and a low of -$34.1 million during Q2 2022
- Its 5-year average for Income towards Parent Company is -$18.6 million, with a median of -$23.6 million in 2021.
- As far as peak fluctuations go, Fulcrum Therapeutics' Income towards Parent Company skyrocketed by 33297.73% in 2024, and later plummeted by 13121.51% in 2025.
- Fulcrum Therapeutics' Income towards Parent Company (Quarter) stood at -$23.5 million in 2021, then dropped by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then fell by 18.27% to -$19.6 million in 2025.
- Its last three reported values are -$19.6 million in Q3 2025, -$17.3 million for Q2 2025, and -$16.6 million during Q4 2024.